GP-2250 Pipeline
Our pipeline includes active studies in the preclinical and clinical phase for pancreatic and ovarian cancers. We are also exploring the full potential of GP-2250 in additional oncology indications as we advance our research activities.
PROMISING PIPELINE
Broad applicability & potential.
Our lead compound, GP-2250, has demonstrated high tumor cell selectivity and broad utility across a variety of cancer indications in preclinical and Phase 1 clinical studies. GP-2250 has also demonstrated suppression of inflammatory cytokine release in multiple preclinical studies.
This unique aspect of GP-2250 potentially opens up clinical benefit and expanded use in several areas of oncology treatments as well as other clinical states where inflammatory cytokine suppression could be of therapeutic value. GP-2250 also has been shown to have broad antimicrobial activity. Additionally, the current clinical trials use an intravenous GP-2250 formulation; however, preclinical in vivo evidence indicates a GP-2250 oral formulation is highly likely and this development will be pursued.
Participate
Become a clinical investigator or patient participant.
Are you a clinician or patient who is interested in learning about or participating in our active studies?
Science
Discover our novel mechanism of action.
Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.